Dawn Biopharma
InvestorActiveDawn Biopharma is an investment platform controlled by the KKR Healthcare Strategic Growth Fund II, founded in 2022 and incorporated in Delaware, with operational offices in London. It was established to own and support a diverse portfolio of life sciences companies focused on the development of innovative medicines and therapies. The platform provides flexible capital across Seed through Series C+ stages. As of mid-2026, Dawn Biopharma has made 9 investments across Europe (primarily Denmark, Belgium, and France), with portfolio companies including Adcendo, Antag Therapeutics, Adcytherix, Bambusa Therapeutics, Vivoryon Therapeutics, and AgomAb Therapeutics (IPO exit). The firm is led by Managing Partner Iyona Rajkomar and frequently co-invests alongside Novo Holdings, RA Capital Management, Pontifax, and Gilde Healthcare.
Founder Intel
Sign in to read intel from founders who have worked with Dawn Biopharma.
What founders say about Dawn Biopharma
Be the first to share intel on Dawn Biopharma — it's free.
Get Started FreeRelated on The List
- 8VC — Investor · Austin, TX, USA
- AlbionVC — Investor · London, UK
- AMR Action Fund — Investor · Geneva, Switzerland
- Angelor — Investor · Lyon, France
- Artis Ventures — Investor · San Francisco, CA, United States
Comparing options? Founders discuss fundraising in the forum, or browse the rest of The List.